Browse Articles
Additional files for manuscripts published before Volume 14 Issue 6 can be found via the abstract link.
Articles published electronically ahead of print and our archive from Volume 4 Issue 1 to Volume 24 Issue 7 can be found below. Articles published earlier will be made available as soon as possible. If you require an article that cannot be found below, please contact the Editorial Office.
Free
Case report
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19
Xiangyang Xie, Yuanliang Jiang, Yuan Zeng, Hui Liu
Antiviral Therapy 2020; 25:233-239
Free
Short communication
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system
Michael A Jarvis, Frederick A Hansen, Kyle Rosenke, Elaine Haddock, Christopher Rollinson, Simon Rule, Graham Sewell, Andrew Hughes, Heinz Feldmann
Antiviral Therapy 2020; 25:223-231
Original article
Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B
Boris JB Beudeker, Zwier MA Groothuismink, Robert A de Man, Harry LA Janssen, Annemiek A van der Eijk, Andre Boonstra, Milan J Sonneveld
Antiviral Therapy 2020; 25:217-222
Original article
Dynamics of HBV surface antigen related end points in chronic hepatitis B infection: a systematic review and meta-analysis
Yusi Chen, Justin Jinhui Li, Rong Chen, Gailing Li, Jia Ji
Antiviral Therapy 2020; 25:203-215
Original article
DAA-based treatment for HIV–HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study
Loredana Alessio, Lorenzo Onorato, Vincenzo Sangiovanni, Francesco Borrelli, Elio Manzillo, Vincenzo Esposito, Filomena Simeone, Salvatore Martini, Nicolina Capoluongo, Sebastiano Leone, Giovanni Di Filippo, Maurizio D’Abbraccio, Lucia Aprea, Angelo Salomone Megna, Eugenio Milano, Viviana Rizzo, Annalisa Saracino, Nicola Coppola
Antiviral Therapy 2020; 25:193-201
Review
The effects of nucleoside/nucleotide analogues on host immune cells: the baseline for future immune therapy for HBV?
Lauke L Boeijen, Michelle Spaan, André Boonstra
Antiviral Therapy 2020; 25:181-191
Original article
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects
Maribel Reyes, Justin D Lutz, Audrey H Lau, Anuj Gaggar, Ethan P Grant, Adarsh Joshi, Richard L Mackman, John Ling, Susanna K Tan, Natarajan Ayithan, Stephane Daffis, Jacky Woo, Peiwen Wu, Tina Lam, Simon P Fletcher, Shyamasundaran Kottilil, Bhawna Poonia, Edward J Gane, Anita Mathias, Polina German
Antiviral Therapy 2020; 25:171-180
Original article
Activation of HIV-specific CD8+ T-cells from HIV+ donors by vesatolimod
Renee R Ram, Paul Duatschek, Nicolas Margot, Michael Abram, Romas Geleziunas, Joseph Hesselgesser, Christian Callebaut
Antiviral Therapy 2020; 25:163-169
Free
Original article
Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes
Adrien Foca, Ammen Dhillon, Thomas Lahlali, Julie Lucifora, Anna Salvetti, Michel Rivoire, Amy Lee, David Durantel
Antiviral Therapy 2020; 25:151-162
Original article
Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China
Quan Zhang, Xiaoming Li, Shan Qiao, Zhiyong Shen, Yuejiao Zhou
Antiviral Therapy 2020; 25:143-149